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Abstract  29 
Purpose: To evaluate outcomes of high myopic LASIK using the MEL 80 excimer laser. 30 
Methods: Retrospective analysis of 479 consecutive high myopic LASIK procedures (318 patients) 31 
using the MEL 80 excimer laser (Carl Zeiss Meditec) and VisuMax femtosecond laser (Carl Zeiss 32 
Meditec) in 77% of cases or zero compression Hansatome (Bausch & Lomb) microkeratome in 23% 33 
of cases. Inclusion criteria were preoperative spherical equivalent refraction (SEQ) of between -8.00 34 
D to -14.25 D, and CDVA of 20/20 or better. Patients were followed for a minimum of 1 year. Flap 35 
thickness was between 80-160 µm and optical zone was between 5.75-6.50 mm. Standard outcomes 36 
analysis was performed. 37 
Results: Mean attempted SEQ was -9.39±1.22 D (-8.00 D to -14.18 D) and mean cylinder was -38 
1.03±0.84 D (0.00 D to -4.50 D). Mean age was 37±9 (21 to 60) with 54% female patients. Of this 39 
population 69% were treated by DZR and 31% by GIC. Postoperative SEQ was ±0.50 D in 55% and 40 
±1.00 D in 83% of eyes, after primary treatment. After retreatment, 69% of eyes were ±0.50 D and 41 
95% were within ±1.00 D. UDVA was 20/20 or better in 89% of eyes after final treatment. One line of 42 
CDVA was lost in 3% of eyes and no eyes lost two or more lines. Statistically significant increases 43 
(p<0.001) were measured in contrast sensitivity (CSV-1000) at 12 and 18 CPD. 44 
Conclusions: The MEL 80 excimer laser was found to achieve high efficacy and safety for treatment 45 
of high myopia between -8.00 D and -14.25 D and up to -4.50 D of cylinder. 46 
  47 
  
Introduction 48 
In the 1990s many studies were published reporting PRK and LASIK correction of very high myopia 49 
(up to -32.00 D in some cases),1-6 however, these treatments were associated with low predictability, 50 
significant regression, and induced night vision disturbances.7-9 During this period, it was found that 51 
these issues were in large part due to the use of small optical zones,10, 11 and the non-aspheric 52 
Munnerlyn ablation profiles leading to significant induction of spherical aberration.12 By 1998, authors 53 
concluded that LASIK was not an appropriate treatment for very high myopia above -15.00 D6 and 54 
were suggesting that phakic intraocular lens (IOL) implantation was more appropriate. Over the next 55 
10 years, consensus shifted towards using phakic IOLs for high myopia and published LASIK studies 56 
rarely included myopia above -10.00 D. For example, the German Commission for Refractive 57 
Surgery’s guidelines state that laser correction should only be considered up to -8.00 D.13   58 
 59 
This thinking was further reinforced when a Cochrane review was published in 201014 (and updated in 60 
201415), which compared laser refractive surgery and phakic IOLs for the treatment of high myopia. 61 
This review concluded that “at one year post surgery, phakic IOLs are safer than excimer laser 62 
surgical correction for moderate to high myopia in the range of -6.00 to -20.00 D and phakic IOLs are 63 
preferred by patients”. However, by applying the rigorous Cochrane method, only three studies met 64 
the inclusion condition of being a randomized control trial (RCT), so the conclusion was based on a 65 
total of 114 eyes each for LASIK and phakic IOL. Furthermore, the LASIK studies were for first and 66 
second generation excimer lasers, two published in 2002 and one in 2007, in which smaller optical 67 
zones and/or non-aspheric ablation profiles had been used.16-18 Therefore, this review had not 68 
considered modern flying spot excimer lasers, advances in eye-tracking, and ablation profile design 69 
including the use of larger optical zones, wavefront-optimized aspheric profiles,19, 20 modern 70 
algorithms for compensation for fluence projection and reflection errors,21 biomechanical factors22 and 71 
the availability of topography-guided ablation profiles.23 Advances in femtosecond laser technology 72 
also allow ultra-thin flaps,24 thereby preserving stromal tissue and reducing the risk of ectasia. 73 
 74 
The comparison should also have been considered in the context of safety. The main risks for high 75 
myopic LASIK are inducing night vision disturbances or keratectasia.25-28 However, phakic IOLs can 76 
also cause night vision disturbances,29 and also introduce less common but potentially serious 77 
  
complications associated with intraocular surgery such as malignant glaucoma, sub-capsular cataract, 78 
damage to zonules, macular edema, suprachoroidal hemorrhage, retinal detachment and 79 
endophthalmitis.29-31 Each type of lens also has specific complications that may require intraocular 80 
surgical intervention (over/undersized lens requiring exchange, explantation, cataract, rotation). 81 
Anterior chamber lenses can cause chronic endothelial cell loss31-33 with an incidence of 0.8% in one 82 
study,33 although another study showed no change in endothelial cell count over 10 years, but 83 
concluded this might be related to surgeon expertise.34 Cataract formation in posterior chamber 84 
lenses has been reported to occur in 8.48% of myopic eyes, requiring lens explantation in 3.4% of all 85 
eyes.30 86 
 87 
The aim of our study was to report outcomes for a large high myopic LASIK population using the MEL 88 
80 excimer laser (Carl Zeiss Meditec, Jena, Germany). We also set out to compare other methods for 89 
high myopia correction with respect to safety and efficacy. 90 
  91 
  
Methods 92 
Patients 93 
This was a retrospective case series of consecutive high myopic LASIK procedures by two 94 
experienced surgeons (DZR & GIC) using the MEL 80 excimer laser and VisuMax femtosecond laser 95 
(both Carl Zeiss Meditec) or zero compression Hansatome microkeratome (Bausch & Lomb) at the 96 
London Vision Clinic, London, UK. Inclusion criteria were attempted spherical equivalent refraction 97 
correction of -8.00 D or higher for the primary procedure, medically suitable for LASIK, no signs of 98 
keratoconus, no previous ocular, eyelid or orbital surgery, no visually significant cataract, and 99 
corrected distance visual acuity (CDVA) 20/20 or better. A minimum follow-up of 1 year was applied. 100 
Informed consent and permission to use their data for analysis and publication was obtained from 101 
each patient prior to surgery as part of our routine preoperative protocol. 102 
 103 
A full ophthalmologic examination was performed before surgery by an in-house optometrist, as has 104 
been described previously.19 Manifest refraction was performed using a standardized and validated 105 
protocol.35 The manifest refraction was repeated on or before the day of surgery by the surgeon, 106 
which was used for treatment planning. Laser data entry was calculated using a multivariate 107 
regression derived nomogram including sphere, spherical aberration precompensation level (see 108 
below), cylinder, age, and flap thickness. 109 
 110 
Planning 111 
In our protocol for treating high myopia, the predicted residual stromal thickness (RST) must be 112 
greater than 250 µm. For some eyes, this meant planning the treatment to be performed in two 113 
stages, so that the RST available for further correction could be accurately assessed before planning 114 
the second procedure. RST was calculated including safety biases for corneal thickness, flap 115 
thickness and ablation depth.36 The minimum of 10 central handheld ultrasound pachymetry 116 
measurements was used, less a further 15 µm to allow for the mean overestimation based on our 117 
comparison to Artemis very high-frequency digital (VHF) ultrasound (Personal communication, Dan Z 118 
Reinstein, 01/09/2006). For flaps created with the zero compression Hansatome using the 160 µm 119 
head, we had previously measured our mean central flap thickness to be 119±13 µm.37  By using a 120 
160 µm flap thickness in the safety calculation, this incorporated a safety bias of 41 µm, meaning that 121 
  
the achieved central flap thickness would be thicker than 160 µm in only 0.8% of eyes. Similarly, a 122 
bias of 18 µm was added to the programmed VisuMax flap thickness, based on our previous study 123 
that found the mean central flap thickness to be 2 µm thicker than programmed with a standard 124 
deviation of 7.9 µm.38 Finally, ablation depth was adjusted according to our previous study which 125 
found the MEL 80 ablation depth readout overestimated achieved ablation depth by approximately 126 
20%,39 plus an additional 5 µm bias. Postoperative keratometry was not included as part of the 127 
suitability assessment; this parameter was formerly used because it acts as a surrogate for induced 128 
spherical aberration, but we can now measure the spherical aberration directly. 129 
 130 
Patients in whom full correction could not be achieved using the above RST calculations, a two-stage 131 
protocol was used where the primary procedure was an intentional undercorrection, followed by a 132 
retreatment according to the criteria set out below. 133 
 134 
All patients were given extra consent forms that described the greater risks associated with treating 135 
high myopia by LASIK relative to lower corrections, including discussion of night vision disturbances, 136 
and refractive accuracy and stability. If a full correction was not possible or the RST indicated that 137 
further treatment would be unlikely, another extra consent form was used to clarify that only one 138 
treatment might be possible. The alternative of phakic IOL surgery was explained to all patients and 139 
that this would enable a full correction. Patients then decided which option to take after weighing up 140 
the relative risks and benefits. 141 
 142 
Surgical Protocol 143 
All treatments were performed as bilateral simultaneous LASIK. The Hansatome was used between 144 
08/08/2003 and 23/07/2010 in 23% and the VisuMax between 13/04/2007 and 29/12/2011 in 77% of 145 
eyes. The procedure was performed by surgeon DZR in 69% and by surgeon GIC in 31% of eyes. 146 
The CRS-Master software platform (Carl Zeiss Meditec, Jena, Germany) was used to generate the 147 
ablation profiles (version 1.1 until 08/11/2004, version 1.3 until 01/03/2007, version 2.1.6 until 148 
01/11/2009, version 2.3.0 thereafter).  149 
 150 
  
The standardized surgical technique has been described previously.40, 41 Both the flap and corneal 151 
ablation were centered on the coaxially sighted corneal light reflex (CSCLR),42 used as the best 152 
approximation of the intersection of the visual axis with the cornea.43 153 
 154 
The ablation profile used the Tissue Saving Ablation (TSA) profile for the correction of sphere and 155 
cylinder, but also included a predetermined level of spherical aberration pre-compensation with a Z40 156 
value ranging up to 1.21 µm (6 mm zone equivalent). Optical treatment zone diameter for first (TSA) 157 
profiles was 5.75 mm in 7%, 6.00 mm in 87%, 6.25 mm in 3%, and 6.50 mm in 3% of eyes. The 158 
spherical aberration component was treated at the same diameter as the base ablation in 30% and at 159 
a 7.00 mm diameter in 70% of eyes. In patients with thinner corneas, the optical zone was reduced to 160 
less than 6.00 mm in order to maximize the correction, with the patient counselled for greater risk of 161 
night vision disturbances. In patients with very large dark pupil diameter, the optical zone was 162 
increased if possible according to corneal thickness. 163 
 164 
Intended flap thickness was 160 µm in 23% with the Hansatome, and 80-85 µm in 47%, 90-100 µm in 165 
29%, and 110 µm in 2% of eyes using the VisuMax. Flap diameter ring used was 8.5 mm in 14% and 166 
9.5 mm in 9% of eyes using the Hansatome, while flap diameters with the VisuMax were 8.0 mm in 167 
70%, 8.5 mm in 1%, and 8.8 mm in 5% of eyes. For VisuMax flaps, a small (S) contact glass was 168 
used for a 8.0 mm flap diameter otherwise a medium (M) contact glass was used. A 5 mm superior 169 
hinge was used in all VisuMax cases. 170 
 171 
Where a full correction was performed, we included an age dependent target hyperopic spherical 172 
refraction for all patients younger than 42 years according to a linear function whereby the target 173 
sphere was +0.66 D for a 21 year old decreasing to plano for a 42 year old. Our micro-monovision 174 
protocol19 was used for all patients older than 42 years, where the target sphere is plano for the 175 
dominant eye and -1.50 D for the non-dominant eye for the majority of patients. 176 
 177 
Postoperative Course and Evaluation 178 
Patients were instructed to instill tobramycin & dexamethasone (Tobradex: Alcon, Fort Worth, TX, 179 
USA) and ofloxacin (Exocin: Allergan Ltd, Marlow, UK) four times daily and wear plastic shields for 180 
  
sleeping during the first week. The surgeon reviewed the patient at day one and measured spherical 181 
refraction and uncorrected distance visual acuity (UDVA); if necessary, flap adjustments were 182 
performed at the slit-lamp using a surgical spear under topical anesthetic and antibiotic cover. An 183 
optometrist examined the patient at one, three, and twelve months and then yearly thereafter. All 184 
visits included measurements of monocular and binocular UDVA, manifest refraction, and corrected 185 
distance visual acuity (CDVA). Best-spectacle-corrected mesopic contrast sensitivity was performed 186 
at the 3 month visit to compare to baseline. ATLAS corneal topography (Carl Zeiss Meditec, Jena, 187 
Germany) and WASCA aberrometry (Carl Zeiss Meditec, Jena, Germany) were performed at 3 188 
months, 1 year and 2 years.  189 
 190 
Retreatments 191 
Retreatments followed the same protocol full correction and two-stage patients. Retreatments were 192 
performed once stability was demonstrated after at least 6 months, defined as no change in sphere 193 
and cylinder within ±0.25 D over an interval of at least two months. A topography-guided ablation23 194 
was used if the patient reported significant night vision disturbances and it was demonstrated that full 195 
spectacle correction alone did not improve night vision disturbances whereas spectacles plus one 196 
drop of brimonidine 0.5% did improve night vision disturbances. 197 
 198 
In the majority of cases (66%), where the predicted RST was less than 275 µm, a VHF digital 199 
ultrasound scan was performed to obtain layered pachymetric maps of corneal, epithelial and residual 200 
stromal thickness.44 The RST map was used to identify the thinnest point and applied in the RST 201 
safety calculation. The retreatment was planned such that the predicted RST after the retreatment 202 
was at least 250 µm at the location of the maximum ablation as well as the location of the minimum 203 
RST. Therefore, in some cases, the retreatment was not necessarily a full correction. 204 
 205 
Statistical Analysis 206 
Outcome analysis was performed according to the Standard Graphs for Reporting Refractive 207 
Surgery.45 Outcomes were analyzed separately for primary treatment data only, and after the final 208 
treatment. Data from the 2 year visit were used for analysis if available, otherwise 1 year data was 209 
used. Stability of keratometry was evaluated by calculating the mean simulated keratometry at 3 210 
  
months, 1 year and 2 years. The change in higher order aberrations was assessed by the change in 211 
coma, spherical aberration and higher order RMS, using a 6 mm analysis zone. Student’s t-tests were 212 
used to calculate the statistical significance of changes in log contrast sensitivity. Microsoft Excel 213 
2010 (Microsoft Corporation, Seattle, WA, USA) was used for data entry and statistical analysis. A p-214 
value <0.05 was defined as statistically significant.  215 
  
Results 216 
Patient Population 217 
During the study period, 527 eyes were treated and one year data were available for 479 (91% follow-218 
up), for which the last timepoint after the primary procedure was 2 years in 48% (n=230), 1 year in 219 
46% (n=221), and 6 months in 6% (n=27) of eyes. All eyes where the last timepoint after the primary 220 
procedure was earlier than 1 year had undergone retreatment at that time. For these eyes, 1 year 221 
follow-up after the retreatment were used to analyze the final outcome. Table 1 shows the 222 
demographic data for the study population. 223 
 224 
Retreatments 225 
The primary procedure was performed as a partial correction (two-stage protocol) in 16% (79/479) of 226 
eyes, of which 71% (56/79) have undergone a retreatment. Of the 400 full correction eyes, 16% 227 
(64/400) have undergone a retreatment. Including all eyes, 25% (120/479) of eyes have undergone a 228 
retreatment, of which 95% (114/120) were performed as a flap lift, 2.5% (3/120) as a PRK procedure, 229 
1.7% (2/120) as a VisuMax LASIK procedure, and 0.8% (1/120) using the VisuMax sidecut only 230 
option (to create a flap within the original flap to avoid a zone of epithelial ingrowth scarring). A 231 
topography-guided custom ablation profile was used for 8 eyes, which constitutes 1.7% of all 479 232 
eyes treated (6.7% of the 120 retreatments performed), and was used to correct for a decentration in 233 
5 eyes, and to enlarge the optical zone in 3 eyes. The scotopic pupil diameter (mean 6.04 mm, range: 234 
5.34 to 7.10 mm) of this sub-group was not different to that of the population (p=0.282). 235 
  236 
  
Standard Outcomes 237 
Figure 1 shows the outcomes for primary treatments only. Figure 2 shows the final outcomes, 238 
including retreatments. 239 
 240 
Table 2 shows the normalized contrast sensitivity data preoperatively and after the final treatment. 241 
There was no change at 3 and 6 cpd, and small but statistically significant increase at 12 and 18 cpd 242 
(p<0.001). Table 3 summarizes the ocular aberrations preoperatively and after the primary treatment. 243 
Coma and higher order RMS were increased, as well as spherical aberration which increased by an 244 
average of 0.49 µm. ATLAS keratometry data showed that the mean keratometry was 38.09±1.65 D 245 
(range: 32.85 to 42.75 D, n=374) at 3 months, 38.27±1.46 D (range: 34.57 to 42.51 D, n=297) at 1 246 
year, and 38.36±1.47 D (range: 34.06 to 41.98 D, n=168) at 2 years. For 238 eyes with keratometry 247 
data at both 3 and 12 months, the mean change was 0.22±0.43 D (range: -1.72 to 1.67 D, p<0.01). 248 
For 116 eyes with keratometry data at both 1 and 2 years, the mean change was 0.11±0.33 D (range: 249 
-0.88 to 1.43 D, p<0.01). 250 
 251 
Complications 252 
In the 109 eyes with flaps created using the Hansatome there were no intraoperative complications 253 
other than small epithelial defects requiring bandage contact lenses in 3 eyes (2.8%). The appendix 254 
details intraoperative complications for VisuMax flaps and postoperative complications in all eyes. 255 
Overall, across the 31 eyes that had intraoperative and/or postoperative complications, 1 eye lost 1 256 
line of CDVA and none lost more than 1 line. 257 
  258 
  
Discussion 259 
The present study found the treatment of myopia between -8.00 D and -14.25 D using the MEL 80 260 
excimer laser and either the VisuMax femtosecond laser or zero compression Hansatome 261 
microkeratome to be safe and effective. While there was an increase in higher order aberrations, as 262 
expected for a high myopic correction, this increase was not excessive as demonstrated by no 263 
reduction in contrast sensitivity. Safety in terms of change in CDVA was also excellent with no eyes 264 
losing 2 lines, 3% losing one line, and 50% gaining one line. While night vision disturbances were not 265 
objectively measured, a topography-guided retreatment was available for any patients reporting 266 
significant symptoms, but was only used in 8 eyes (1.7%) demonstrating that few patients 267 
experienced visually significant night vision disturbances. 268 
  269 
In order to compare the current study to published LASIK and phakic IOL studies, we performed a 270 
literature review for studies published within the last five years reporting results of myopia above -8.00 271 
D. The main outcome parameters are shown  in Table 4,16-18, 32, 46-50 as well as the studies included in 272 
the Cochrane review. The results of the present study were similar in terms of accuracy, efficacy and 273 
safety to those reported in the last five years for both LASIK and phakic IOLs, although the range 274 
treated was much higher for phakic IOLs (e.g. up to -23.00 D50). Nevertheless, as discussed earlier, 275 
intraocular surgery introduces potential, albeit unusual, serious visual complications. While ectasia 276 
can occur many years after surgery,51 with modern keratoconus screening techniques,52, 53 inclusion 277 
of biases for calculating predicted RST, direct measurement of RST before retreatment surgery, and 278 
the availability of corneal cross-linking,54 the risk of ectasia is significantly lower than 10 years ago. 279 
 280 
It is important to note that the present study and other recent LASIK studies46-48 appear to contradict 281 
the conclusion from the Cochrane review;14, 15 these results are significantly better than those of both 282 
LASIK and phakic IOLs reported for studies included in the Cochrane review. The predictability 283 
ranged from 29% to 57% within ±0.50 D for the LASIK/PRK groups and from 24% to 76% for the 284 
phakic IOL groups in the Cochrane review, whereas the range was from 69% to 100% for recent 285 
LASIK studies. Similarly, postoperative UDVA was 20/20 or better in 12% to 84% in the LASIK/PRK 286 
groups and 20% to 97% in the phakic IOL groups in the Cochrane review, whereas the range was 287 
77% to 92% for recent LASIK studies. Finally, safety was much worse for the LASIK groups in the 288 
  
Cochrane review with a loss of 2 or more lines of CDVA between 4%18 and 12% of eyes,16 whereas 289 
no eyes lost even 2 lines in the recent LASIK studies. Therefore, it appears that the Cochrane 290 
review14, 15 only included studies that would be considered out-of-date, and the conclusions while 291 
applicable to earlier technology and protocols do not apply to modern LASIK. This demonstrates the 292 
limitation of the Cochrane review methodology to refractive surgery, as very few studies meet the 293 
strict criteria of being randomized control trials. This is further emphasized by the fact that the 201415 294 
update found no new studies meeting the inclusion criteria. While the Cochrane review methodology 295 
clearly represents a robust method scientifically, it suffers when applied to refractive surgery as the 296 
majority of studies reporting surgical outcomes are retrospective for obvious reasons. This however 297 
highlights the paucity of randomized controlled trials, outside of United States Food and Drug 298 
Administration trials,55 as a weakness of the refractive surgery field.  299 
 300 
In summary, LASIK for high myopia up to -14.25 D using modern technology was found to have 301 
similar outcomes to phakic IOLs, while avoiding the potentially serious complications associated with 302 
intraocular surgery.  303 
  
Legends 304 
Figure 1: Nine standard graphs for reporting refractive surgery showing the visual and refractive 305 
outcomes for 479 high myopic eyes after initial treatment with the MEL 80 excimer laser and the 306 
VisuMax femtosecond laser (both Carl Zeiss Meditec) or the zero compression Hansatome 307 
microkeratome (Bausch & Lomb). UDVA = uncorrected distance visual acuity; CDVA= corrected 308 
distance visual acuity; D = diopters; Postop = postoperative; Preop = preoperative; SEQ = spherical 309 
equivalent refraction; TIA = target induced astigmatism; SIA = surgically induced astigmatism. 310 
 311 
Figure 2: Nine standard graphs for reporting refractive surgery showing the visual and refractive 312 
outcomes for 479 high myopic eyes after final treatment with the MEL 80 excimer laser and the 313 
VisuMax femtosecond laser (both Carl Zeiss Meditec) or the zero compression Hansatome 314 
microkeratome (Bausch & Lomb). UDVA = uncorrected distance visual acuity; CDVA= corrected 315 
distance visual acuity; D = diopters; Postop = postoperative; Preop = preoperative; SEQ = spherical 316 
equivalent refraction; TIA = target induced astigmatism; SIA = surgically induced astigmatism. 317 
  318 
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Intraoperative complications 
 
Occurrences 
Percentage 
of Total 
Epithelial Defect 8 2.2% 
Suction Loss 7 1.9% 
Incomplete Flap (Edge) 2 0.5% 
Incomplete Flap (Ablation Zone) 1 0.3% 
Buttonhole 4 1.1% 
Free Cap 0 0% 
Irregular Bed 0 0% 
Flap Tear 1 0.3% 
 
Postoperative complications requiring flap lift 
 
Occurrences 
Percentage 
of Total 
Flap Lift for Trauma 1 0.3% 
Flap Lift for Epithelial Ingrowth  2 0.5% 
Flap Lift for Microfolds 1 0.3% 
Flap Lift for Interface Deposits 1 0.3% 
 
Intraoperative Complications 
Hansatome treated eyes: There were no intraoperative complications in the 109 eyes treated using 
the Hansatome microkeratome other than a small epithelial defect requiring a bandage contact lens in 
3 eyes (2.8%). There was no impact on CDVA in any of these cases. 
 
VisuMax treated eyes: Of the 371 eyes treated using the VisuMax femtosecond laser, a peripheral 
epithelial defect requiring a bandage contact lens occurred in 8 eyes (2.2%). Suction loss occurred in 
7 eyes (1.9%), 5 eyes in which the contact glass was immediately reapplied and flap creation 
completed with the same flap parameters; of these, a perfect flap was created in 4 eyes with the 
stromal bed appearing smooth prior to ablation. In the remaining eye some thin thread-like mid-
peripheral stromal slivers were noted on the stromal bed with the central bed of good quality for 
ablation; the peripheral stromal slivers were repositioned before the excimer laser ablation was 
performed and the flap was repositioned perfectly with no subsequent loss of best spectacle corrected 
vision or contrast sensitivity. The remaining 2 eyes with repeated suction loss belonged to the same 
patient, where after four attempts on the first eye and one attempt on the second eye it was deemed 
  
not possible to adequately create flaps using the VisuMax. After discussion with the patient, the 
procedures were performed instead using the zero compression Hansatome microkeratome without 
further complication. In all 8 eyes that experienced a suction loss, there was no loss of CDVA nor 
contrast sensitivity, and 7 eyes actually experienced a gain of one line of CDVA. Further recorded 
complications in VisuMax treated eyes included one eye (0.3%) with a small tear to the hinge of the 
flap in an eye that subsequently gained two lines of CDVA; a small peripheral flap tear approximately 
1 mm within the flap boundary inferiorly in one eye (0.3%) where the flap lifting instrument perforated 
the flap while manually dissecting through a peripheral zone of dense opaque bubble layer (OBL) due 
to the presence of a small cryptic buttonhole in an 80 (programmed 98) µm flap – after ablation the 
flap was repositioned perfectly, a bandage contact lens was applied and after healing there was no 
change in CDVA. There were 3 eyes (0.8%) in which there was inadequate or no femtosecond cutting 
within a small area of flap interface (centrally in 1 eye, peripherally in 2 eyes); in each case these 
areas could be dissected manually and there was no impact on CDVA or contrast sensitivity. Finally, 
there were 4 eyes (1.1%) in which a small buttonhole was discovered on lifting the flap (centrally in 1 
eye, peripherally in 3 eyes) probably secondary to previous focal contact lens related infections (with 
epithelial plugs). In all cases, after carefully lifting the flap, the residual epithelium overlying Bowman’s 
layer was brushed off to reveal the stromal surface and the ablation was performed and flap replaced 
carefully followed by an overnight bandage contact lens. The eye with a central buttonhole lost one 
line of CDVA. 
 
Postoperative complications requiring flap lift 
A flap lift procedure was required at the 1 day visit to reposition the flap in 1 eye (0.3%) following a 
flap slip due to trauma to the eye overnight. This eye then also required a second flap lift procedure 1 
week later for epithelial ingrowth removal which healed with no ingrowth. One other eye (0.3%) 
required a flap lift procedure for epithelial ingrowth following a retreatment procedure. A flap lift 
procedure was performed for 1 eye (0.3%) to treat microfolds at the 1 month timepoint. A flap lift 
procedure was performed for 1 eye (0.3%) to remove inorganic deposits from the flap interface. There 
was no impact on CDVA in any of these cases. 
 
  
Table 1: Study demographics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Number of Eyes (patients) 479 (318) 
Age (years) 
37±9 
(21 to 60) 
Gender Ratio (M/F %) 46 / 54 
Attempted Spherical 
Equivalent Refraction (D) 
-9.39±1.22 
(-8.00 to -14.18) 
Attempted Cylinder (D) 
-1.03±0.84 
(0.00 to -4.50) 
Scotopic pupil (mm) 
5.80±1.04 
(3.36 to 8.40) 
  
Table 2: Normalized mesopic contrast sensitivity (CSV-1000) 
 
 
 
CPD: Cycles Per Degree 
  
 3 CPD 6 CPD 12 CPD 18 CPD 
Pre 0.99±0.11 0.94±0.09 0.91±0.13 0.84±0.19 
Post 0.98±0.11 0.94±0.09 0.93±0.13 0.87±0.20 
p-value 0.127 0.249 <0.001 <0.001 
  
Table 3: Ocular Aberrations (µm) 
 
HORMS: High Order Root Mean Square 
 
 
 
 Pre Post Change t-test 
Coma 0.169±0.103 0.266±0.201 0.100±0.221 p<0.001 
Spherical Aberration 0.135±0.148 0.626±0.222 0.491±0.074 p<0.001 
HORMS 0.324±0.109 0.737±0.198 0.426±0.196 p<0.001 
  
            Accuracy UDVA Safety 
First Author N (eyes) Technique Preop SEQ (D) Age (years) FU 
Mean±SD (D) 
(range) ±0.50 ±1.00 
Pre 
CDVA 
≤20/20 
≤20/20 ≤20/40 1 line ≥2 lines 
Reinstein 
2014 483 
LASIK 
VisuMax/Hansatome 
CZM MEL80 
-9.57±1.29 
(-7.50 to -14.18) 
36.8±9.4 
(21 to 60) 
1-2 
years 
-0.26±0.47 
(-2.25 to +1.13) 69% 95% 100% 89% 99% 3% 0% 
Kanellopoulos 
2013 116 
LASIK 
Wavelight FS200 
Wavelight EX500 
-7.67±1.55 
(-6.00 to -13.00) 
28.7 ± 7.5 
(17 to 51) 
3 
months -0.37±0.08 89% 95% 73% 90.5% 97.4% 1.7% 0% 
Vega-Estrada 
2012 29 
LASIK 
IntraLase 
Schwind AMARIS 
-8.39±0.93 
(-6.75 to -11.25) 
36.7 ±10.8 
(24 to 61) 
6 
months 
-0.42±0.82 
(-3.50 to +0.63) - 89.6% - - - - - 
Stonecipher 
2010 65 
LASIK 
IntraLase 
Alcon Allegretto 
Wave 400Hz 
-7.07±0.89 
(-6.86 to -12.63) 
33.8 
(20 to 60) 
6 
months - 100% 100% - 92% 100% - 0% 
Stonecipher 
2010 141 
LASIK 
IntraLase 
Alcon Allegretto 
Wave 200Hz 
-6.76±1.01 
(-6.08 to -11.05) 
33.8 
(20 to 60) 
6 
months - 86% 100% - 77% 100% - 0% 
Hashemi 
2014 23 
PRK-MMC 
VISX STAR S4 
-8.82±1.25 
(≤ -8.00) 28.7±5.3 1 year -0.25±0.41 85.7% - 76.2% 57.1% - 9.5% 0% 
Hashemi 
2014 23 
Phakic IOL 
Artiflex 
-9.49±1.94 
(≤ -8.00) 27.7±5.3 1 year -0.17±1.17 95.7% - 95.7% 73.9% - 0% 0% 
Ju 
2013 82 
Phakic IOL 
STAAR ICL 
-15.56±4.35 
(-9.00 to -23.00) 
28.6 ± 7.6 
(19 to 45) 
3 
months -1.85±0.72 72.5% 88% 45% 58.5% 92.7% 3.7% - 
Knorz 
2011 104 
Phakic IOL 
AcrySof Cachet 
-10.41±2.31 
(-6.00 to -16.50) 
36.6 ± 8.1 
(18 to 53) 3 years 
-0.24±0.55 
(-2.00 to +1.63) 78.8% 91.3% 100% 71.2% 98.1% 1% 1% 
Alió 
2014 40 
LASIK 
VISX 20/20 (-6.00 to -18.00) 
51.1±6.7 
(35 to 60) 15 years -1.37±2.21 - 46.2% - 43.6% 64.1% 10.3% 0% 
Oruçoğlu 
2012 
143 
39 FU 
LASIK 
Technolas 
-21.70±5.80 
(-38.00 to -14.13) - 10 years 
-6.09±3.35 
(-14.38 to -0.50) - 
14% 
1 year - - 2.6% 10.3% - 
El Danasoury 
2002 45 
LASIK 
NIDEK EC-5000 
-13.24±2.30 
(-9.13 to -17.50) 
33.7±7.1 
(21 to 47) 1 year 
-0.87±0.8 
(-3.00 to -1.00) 29% 56% - 12.2% 58.5% - 12.2% 
El Danasoury 
2002 45 
Phakic IOL 
Artisan 
-13.93±2.90 
(-9.50 to -19.38) 
33.7±7.1 
(21 to 47) 1 year -0.64±0.8 42% 65% - 20.9% 88.4% - 0% 
Malecaze 
2002 25 
LASIK 
Hansatome 
Technolas 
-9.39±1.47 
(-8.00 to -12.00) 
38.4±7.6 
(31 to 52) 1 year -0.74±0.67 44% 64% - 24% 80% 20% 4% 
  
Malecaze 
2002 25 
Phakic IOL 
Artisan 
-10.19±1.56 
(-8.00 to -12.00) 
38.4±7.6 
(31 to 52) 1 year -0.95±0.45 24% 60% - 20% 60% 12% 0% 
Schallhorn 
2007 45 
PRK 
VISX S3 -8.30±1.25 32.6±7.0 1 year +0.60±0.75 57% 80% 89% 82% - 7% 0% 
Schallhorn 
2007 43 
Phakic IOL 
TICL -8.04±1.28 30.8±6.0 1 year +0.27±0.36 76% 100% 93% 97% - 0% 0% 
 


